Bristol Myers Squibb
BMS Acquires Orum’s ADC ORM-6151 for AML and MDS Treatment
Bristol Myers Squibb (BMS) has made a significant move in the field of antibody-drug conjugates (ADCs) by acquiring Orum Therapeutics’ ...
Bristol Myers’ new CEO aims to boost weak new drug launches
Bristol Myers Squibb (BMS) is addressing concerns about its underperforming new products, expressing confidence in their future success. The company’s ...
Opdivo Beats Chemo in First-Line Bladder Cancer, But Keytruda-Padcev Combo Looms Large (ESMO 2023)
ESMO 2023: LBA7 Bladder cancer has presented a unique challenge for immunotherapies, with Bristol Myers Squibb’s Opdivo making strides, but ...
BMS and Halozyme announce positive results for subcutaneous Opdivo in cancer patients
Following the discontinuation of an auto-injected version of Opdivo (nivolumab), Bristol Myers Squibb (BMS) has achieved success with a more ...
Bristol Myers Squibb’s Opdivo gets FDA approval for early-stage melanoma
Bristol Myers Squibb’s Opdivo has achieved a significant milestone with a new FDA approval that expands its reach into earlier ...
Pfizer’s Velsipity gets FDA approval to challenge BMS’ Zeposia in ulcerative colitis market
Pfizer’s groundbreaking approval of its drug, Velsipity, as a once-daily oral treatment for adults suffering from moderate to severe active ...
BMS invests more in Cellares to boost cell therapy manufacturing
Just six weeks following the initial announcement of a partnership between cell and gene therapy manufacturer Cellares and Bristol Myers ...
Bristol Myers Squibb acquires Mirati Therapeutics in a $5.8 billion deal to expand its cancer treatment portfolio
Mirati Therapeutics, long speculated to be a potential acquisition target in the world of Big Pharma, has now sealed a ...
BMS and Paradigm partner to bring clinical trials to community health providers
Bristol Myers Squibb (BMS) has embarked on a transformative collaboration with Paradigm, a groundbreaking startup focused on reimagining the clinical ...
ICER Reviews BMS’ Eliquis, J&J’s Xarelto Amidst Medicare Price Talks
As the United States embarks on a new era of drug price negotiations, the Institute for Clinical and Economic Review ...
Opdivo plus chemo reduces recurrence risk in early-stage lung cancer surgery
In the arena of perioperative treatment for early-stage non-small cell lung cancer (NSCLC) involving PD-1/L1 inhibitors, the competition among key ...
Aurinia appoints founder and former CEO Robert Foster to board as part of cooperation agreement with MKT Capital
Aurinia Pharmaceuticals, known for its focus on autoimmune diseases, has taken steps to address investor concerns by appointing its founder ...
Samsung Biologics expands antibody production deal with Bristol Myers Squibb for $242 million
Samsung Biologics, a leading biopharmaceutical contract manufacturing organization, has strengthened its partnership with Bristol Myers Squibb (BMS) by securing a ...
Bristol Myers Squibb aims for 25+ new indications to overcome patent losses and pricing challenges
Bristol Myers Squibb is placing a significant bet on its robust pipeline to weather challenges such as the Inflation Reduction ...
Bristol Myers Squibb celebrates 10 years of cycling for cancer with a cross-country ride and a $1.5M donation
Bristol Myers Squibb is commemorating a decade of charitable efforts by organizing a 3,000-mile bike ride to support cancer patients. ...
Xspray Pharma settles with BMS over Sprycel generic, awaits FDA nod
Xspray Pharma, which encountered an FDA setback in July, was initially aiming to launch its competitor to Bristol Myers Squibb’s ...
BMS scores another phase 2 win for its pulmonary fibrosis drug
Bristol Myers Squibb (BMS) is making significant strides in the field of pulmonary fibrosis treatment, particularly with its lysophosphatidic acid ...
BMS faces lawsuit for allegedly extending Pomalyst monopoly with fraudulent patents and payoffs
Bristol Myers Squibb (BMS) and Celgene’s widely-used multiple myeloma treatment, Pomalyst, has found itself entangled in a legal battle after ...
BMS acquires regional rights to Zenas’ obexelimab, a bifunctional antibody for autoimmune diseases
Zenas BioPharma has made a strategic move by transferring regional rights for its bifunctional monoclonal antibody, obexelimab. Bristol Myers Squibb ...
Amgen’s Otezla holds its ground against BMS’ Sotyktu in oral plaque psoriasis market, leaving room for J&J’s potential game-changer
Amgen’s bold $13.4 billion investment in Otezla appears to remain robust in the face of competition from Bristol Myers Squibb’s ...
Mezigdomide, a new oral drug for multiple myeloma, shows ‘modest’ survival benefit in phase 1 trial
A new oral drug for multiple myeloma, mezigdomide, has shown a ‘modest’ survival benefit in a phase 1 trial involving ...
Bracing for Change: CMS Unveils Drug Price Negotiation Targets Amid Industry Backlash
The day that pharmaceutical manufacturers have been cautiously eyeing has finally dawned – Tuesday saw the grand revelation of the ...
Bristol Myers Squibb’s Bold Robotic Alliance with Cellares for Advanced CAR-T Production
In the realm of cutting-edge cell therapy, where innovation is the heartbeat and the promise of transformative treatments is the ...
FDA Grants Approval: Reblozyl’s Triumph Ushers in a New Dawn for Anemia Treatment
Bristol Myers Squibb has ushered in a breakthrough in the realm of medical advancements, announcing the FDA’s seal of approval ...
Exploring Real-World Anticoagulant Transitions: Insights Unveiled at the European Society of Cardiology (ESC) Congress 2023
Amidst the vivid tapestry of medical advancements, a pivotal revelation has emerged from the collaborative efforts of the Bristol Myers ...
Cellares Announces $255M Investment Round with Bristol Myers Squibb Among Key Investors
Cellares, a pioneering cell therapy manufacturer based in South San Francisco, has introduced a unique concept in the industry with ...
Novartis Announces New Round of Layoffs at US Headquarters Following Earlier Job Cuts
Novartis, a Swiss pharmaceutical giant, is set to undergo another round of job cuts at its U.S. headquarters in East ...
BMS Layoffs Over 100 Employees Lose Jobs After Earnings Miss
Bristol Myers Squibb, a prominent pharmaceutical company headquartered in New Jersey, has undertaken a significant reorganization of its financial structure ...
The legacy of Bristol Myers and BeiGene Celgene’s payment comes years after China’s prohibition
In 2020, an unexpected manufacturing issue led to a ban on the import of Bristol Myers Squibb’s (BMS) Abraxane, distributed ...
BMS’ Sotyktu is approved for psoriasis usage by the NHS
Source: Bristol-Myers Squibb Just weeks after receiving approval in the UK, Bristol-Myers Squibb’s novel oral therapy for psoriasis, SotyKtu, has ...
